Washington sues over RFK Jr.'s canceled health funding
Vaccination efforts are among the areas affected by the Trump administration's cuts to public health funding. (Photo by)
Washington was among 23 states that sued the Trump administration Tuesday over the cancellation of $12 billion in federal funding to address infectious diseases, substance abuse and mental illness, including about $160 million for Washington.
The lawsuit comes on the heels of the abrupt termination last week of grants related to disease tracking, vaccination efforts and other work that officials said could cost thousands of jobs in public health departments nationwide. This pot of money makes up $11 billion of the $12 billion cut.
The cuts in Washington reportedly include $118 million for the Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases program, impacting 150 full-time employees. Losing this money will hurt the state's ability to respond to emerging outbreaks, including measles and bird flu, according to the complaint.
That money also continued to support COVID-related surveillance efforts, the lawsuit says.
In total, Washington's Department of Health stands to lose around $130 million, an agency spokesperson said last week, with the termination affecting upward of 200 department employees, and more at local health departments, tribal health clinics and community-based organizations.
One of the specific programs affected is Care Connect, which the department launched early in the pandemic to provide food and other needs to people with COVID so they could isolate. The program later shifted to meet the needs of those suffering from long COVID, among other things.
Washington Attorney General Nick Brown also cites the state's Care-A-Van mobile health clinics that provide vaccinations and other services to underserved communities. Officials have already had to cancel clinics due to the lost funding.
The U.S. Department of Health and Human Services rolled back the grants 'for cause' because 'the pandemic is over,' so the funding is no longer needed, according to the lawsuit. The states counter that the money was never intended to only be used to respond to the COVID pandemic.
The lawsuit also tackles the separate but simultaneous Trump administration axing of another $1 billion in Substance Abuse and Mental Health Services Administration funding, including $34 million for Washington.
Brown is one of several attorneys general leading Tuesday's lawsuit, filed in U.S. District Court in Rhode Island. The Department of Health and Human Services and Secretary Robert F. Kennedy Jr. are named as defendants. The department didn't immediately respond to a request for comment Tuesday.
'We can't make America healthy by spreading preventable diseases,' Brown said. 'Aside from the illegality of these actions, the administration is also choosing to neglect the biggest public health challenges, including substance abuse and mental health crises, facing our communities.'
The states say the cuts violate the Administrative Procedure Act by suddenly terminating the grants without much explanation. The plaintiffs asked a judge for a temporary restraining order to reverse the cuts.
The state Department of Health's now-canceled federal grant dollars were expected to expire between June 2025 and July 2026, agency spokesperson Marisol Mata Somarribas said.
Also on Tuesday, the Department of Health and Human Services began its purge of 10,000 federal workers.
As part of the layoff announcement, Kennedy also said he'd be halving the number of Health and Human Services regional offices from 10 to five. Seattle's office serves Washington, Oregon, Idaho and Alaska. Its fate was unclear Tuesday.
This is at least the 8th lawsuit Brown has led or joined against the Trump administration since January. Most have resulted in preliminary court orders blocking implementation of a variety of actions, including eliminating birthright citizenship, blocking gender-affirming care for minors and mass firings of federal workers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
38 minutes ago
- Los Angeles Times
Anaheim Regional Medical Center nurses' union wins pay boost, security upgrades
Registered nurses who work at the Anaheim Regional Medical Center voted to ratify their first-ever labor contract with the hospital on Wednesday night, an agreement they claim will improve patient care. As negotiations carried on, safety remained a top priority for nurses represented by SEIU Local 121RN. The union in April held an info picket outside of the hospital to draw attention to such issues. In the past, nurses and their aides have screened people for weapons and drugs at the hospital's emergency room entrance. While nurses did not gain the walk-through metal detectors they pushed for in bargaining, the hospital has agreed to staff security guards with metal detector wands at different entry points within six months to a year. Security staff will also take over bag searches and provide identification for visitors. 'That's something we're not responsible for anymore,' said Liza Lorenzo, a telemetry nurse who has worked at the hospital for the past 15 years. 'We have more time to do bedside care, as opposed to going through people's belongings, which was not safe for us, as well.' When reached, a spokesperson for AHMC Healthcare, the company that owns the hospital, declined to comment on the contract. The security changes come before Assembly Bill 2975, which the union advocated for and requires hospitals throughout the state to have weapons detection screening policies by March 2027. Nurses also won a minimum 19% pay raise over the four years of the contract. The salary boost comes with additional measures to ensure there are four nurses for every patient at a specialty unit, a ratio mandated by state law. For telemetry units, the nurse-patient ratio is five-to-one. During the pandemic, Lorenzo claimed that the hospital stretched its nurse-to-patient ratios beyond their limits but nurses now have protections in place to hold management accountable. 'We made sure that we have a resource nurse for every five nurses or more,' said Lorenzo, who helped negotiate the contract. 'If there's five nurses in the unit, we will have a resource nurse dedicated for that unit alone. Obviously, better staffing leads to faster response, reduces medical errors and prevents staff burnout.' Nurses are hopeful that the boosted salaries and ratio protections will go a long way toward addressing what they called inadequate staffing at the hospital. The union also proposed forming a pandemic task force following the experience of the COVID-19 pandemic that overwhelmed hospitals in Orange County. The contract guarantees that nurses will have enough personal protective equipment for three months while following U.S. Center for Disease Control and Prevention guidelines. 'We're more prepared in the case of another pandemic, as opposed to just scrambling,' Lorenzo said. As nurses also complained about broken-down MRI machines and the lack of running hot water at times, the hospital has also pledged to make timely repairs to medical equipment while addressing other maintenance issues. Lorenzo beamed with pride when speaking about critical provisions of the newly ratified contract, which arrived in less than one year's time since safety concerns first prompted nurses to unionize in August. 'Our efforts have paid off,' she said. 'Now we have our first contract. This is not only for us, but also for our patients and the community.'
Yahoo
2 hours ago
- Yahoo
Rep. Don Scott to discuss threats to Medicaid in Norfolk
NORFOLK, Va. (WAVY) — Virginia House Speaker Don Scott will join other advocates for reproductive freedom in Norfolk on Friday to speak about the threat to Medicaid. The stop at the Slover Library is the final stop of a statewide tour called 'Protect our Medicaid.' The goal of the tour, according to a release, is to raise awareness of the threat cuts to Medicaid could have on Virginia families. Those with the Protect our Medicaid group said the federal cuts to Medicaid under the Trump Administration's 'Big, Beautiful Bill' could cause over 250,000 Virginians to lose their healthcare, with nearly 47,000 veterans alone in the state covered by Medicaid. The bill includes a proposed $625 million cut in Medicaid — which could cause 7.6 million people nationwide to lose health coverage in less than a decade, according to budget analysis. A release from the group states that Medicaid is the largest source of funding for home care in the United States, with home care for older adults and people with disabilities rising across the country. GOP bill raises fears of major reduction in home care for seniors, disabled The discussion will address how cuts to both Medicaid and Planned Parenthood can impact the Hampton Roads regional economy and how it will harm Virginia families. The Protect our Medicaid tour is expected to be held in the third floor at the Slover Library starting at 11 a.m. Continue to check for updates. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Indianapolis Star
2 hours ago
- Indianapolis Star
Moderna Announces Update on Investigational Pandemic Influenza Program
Phase 1/2 H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna's award for late-stage development of pre-pandemic influenza vaccines CAMBRIDGE, MA / ACCESS Newswire Moderna, Inc. (NASDAQ:MRNA) today announced positive interim data from a Phase 1/2 clinical study (NCT05972174) evaluating the safety and immunogenicity of its investigational pandemic influenza vaccine, mRNA-1018, in approximately 300 healthy adults aged 18 years and older. The interim results focus on a vaccine candidate targeting the H5 avian influenza virus subtype. The Company had previously expected to advance the program to late-stage development with the U.S. Department of Health and Human Services (HHS); however, today Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines. 'While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,' said Stéphane Bancel, Chief Executive Officer of Moderna. 'These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.' The Phase 1/2 study evaluated a two-dose regimen of Moderna's investigational avian influenza vaccine. mRNA-1018 demonstrated a rapid, potent and durable immune response. At baseline, pre-existing immunity was minimal, with only 2.1% of participants showing hemagglutination inhibition (HAI) antibody titers ≥1:40, an HAI titer considered to correlate with protection. At Day 43, three weeks after the second vaccination, 97.8% of participants achieved titers ≥1:40 with a 44.5-fold increase of titers from baseline. The investigational vaccine was generally well-tolerated, with no dose-limiting tolerability concerns observed. Most solicited adverse reactions were Grade 1 or 2 and did not increase significantly with number of doses or between first and second doses. Further data is expected to be submitted for presentation at an upcoming scientific meeting. Moderna will explore alternatives for late-stage development and manufacturing of the H5 program consistent with the Company's strategic commitment to pandemic preparedness. About Moderna Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the clinical development of mRNA-1018, the safety and immunogenicity data from the Phase 1/2 study; the cancellation of the development contract for Moderna's pandemic flu program by the U.S. Department of Health and Human Services; and the exploration of alternative paths for development of the vaccine program. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading 'Risk Factors' in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in subsequent filings made by Moderna with the U.S. Securities and Exchange Commission, which are available on the SEC's website at Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release. Moderna Contacts Investors: Lavina Talukdar Senior Vice President & Head of Investor Relations +1 617-209-5834 SOURCE: Moderna, Inc. View the original press release on ACCESS Newswire
